MA46892A - Composés d'alcène tétrasubstitués et leur utilisation pour le traitement du cancer du sein - Google Patents
Composés d'alcène tétrasubstitués et leur utilisation pour le traitement du cancer du seinInfo
- Publication number
- MA46892A MA46892A MA046892A MA46892A MA46892A MA 46892 A MA46892 A MA 46892A MA 046892 A MA046892 A MA 046892A MA 46892 A MA46892 A MA 46892A MA 46892 A MA46892 A MA 46892A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- breast cancer
- alkene compounds
- tetrasubstituted alkene
- tetrasubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641040196 | 2016-11-24 | ||
| IN201741018583 | 2017-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46892A true MA46892A (fr) | 2021-04-14 |
Family
ID=60703082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046892A MA46892A (fr) | 2016-11-24 | 2017-11-22 | Composés d'alcène tétrasubstitués et leur utilisation pour le traitement du cancer du sein |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20180141913A1 (fr) |
| EP (1) | EP3544974A1 (fr) |
| JP (1) | JP2019535778A (fr) |
| CN (1) | CN110300751A (fr) |
| MA (1) | MA46892A (fr) |
| TW (1) | TW201831453A (fr) |
| WO (1) | WO2018098305A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2747399C2 (ru) | 2016-11-28 | 2021-05-04 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соли производного индазола и их кристаллы |
| WO2019225552A1 (fr) * | 2018-05-22 | 2019-11-28 | Eisai R&D Management Co., Ltd. | Sels de dérivé d'indazole et cristaux associés |
| WO2020253762A1 (fr) * | 2019-06-19 | 2020-12-24 | 江苏恒瑞医药股份有限公司 | Dérivé d'indazole, son procédé de préparation et son application pharmaceutique |
| CN116615418A (zh) * | 2020-12-18 | 2023-08-18 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法 |
| CN114644615B (zh) * | 2020-12-18 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的结晶形式及其制备方法 |
| CN114644616B (zh) * | 2020-12-18 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法 |
| WO2023272410A1 (fr) * | 2021-06-27 | 2023-01-05 | 北京盛诺基医药科技股份有限公司 | ANTAGONISTES DE LIAISON COVALENTE DU RÉCEPTEUR ERα |
| TW202317135A (zh) * | 2021-07-13 | 2023-05-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 選擇性雌激素受體共價拮抗劑與cdk4/6抑制劑聯合在製備治療乳腺癌藥物中的用途 |
| CN115960082B (zh) * | 2021-10-13 | 2024-06-07 | 长春金赛药业有限责任公司 | 一种四取代的烯烃化合物、其制备方法及其在医药上的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2483736B (en) * | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| WO2013142266A1 (fr) * | 2012-03-20 | 2013-09-26 | Seragon Pharmaceuticals, Inc. | Modulateurs de récepteurs d'œstrogènes et leurs utilisations |
| US9845291B2 (en) * | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
| MY186977A (en) * | 2015-05-29 | 2021-08-26 | Eisai R&D Man Co Ltd | Tetrasubstituted alkene compounds and their use |
-
2017
- 2017-11-22 EP EP17817456.1A patent/EP3544974A1/fr not_active Withdrawn
- 2017-11-22 US US15/821,367 patent/US20180141913A1/en not_active Abandoned
- 2017-11-22 CN CN201780084351.7A patent/CN110300751A/zh active Pending
- 2017-11-22 JP JP2019528047A patent/JP2019535778A/ja active Pending
- 2017-11-22 MA MA046892A patent/MA46892A/fr unknown
- 2017-11-22 US US16/349,479 patent/US20200255415A1/en not_active Abandoned
- 2017-11-22 WO PCT/US2017/063047 patent/WO2018098305A1/fr unknown
- 2017-11-24 TW TW106141003A patent/TW201831453A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018098305A1 (fr) | 2018-05-31 |
| US20200255415A1 (en) | 2020-08-13 |
| JP2019535778A (ja) | 2019-12-12 |
| TW201831453A (zh) | 2018-09-01 |
| CN110300751A (zh) | 2019-10-01 |
| EP3544974A1 (fr) | 2019-10-02 |
| US20180141913A1 (en) | 2018-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46892A (fr) | Composés d'alcène tétrasubstitués et leur utilisation pour le traitement du cancer du sein | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| MA50082A (fr) | Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer | |
| MA45192A (fr) | Traitement d'association | |
| MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
| MA47310A (fr) | Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer | |
| MA42136A (fr) | Anticorps anti-cd38 pour le traitement de l'amyloïdose à chaînes légères et d'autres tumeurs malignes hématologiques positives à cd38 | |
| MA52575A (fr) | Pansement pour le traitement de la peau endommagée | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA42439A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
| MA43364A (fr) | Composés d'alcènes tétrasubstitués et leur utilisation | |
| MA39960A (fr) | Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| MA43811A (fr) | Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes | |
| MA55143A (fr) | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau | |
| MA47776A (fr) | Polythérapies pour le traitement du cancer du sein | |
| MA52252A (fr) | Formulation de poudre nasale pour le traitement de l'hypoglycémie | |
| MA50943A (fr) | Anticorps anti-liv1 humanisés pour le traitement du cancer du sein |